Valproate and Short-Chain Fatty Acids Activate Transcription of the Human Vitamin D Receptor Gene through a Proximal GC-Rich DNA Region Containing Two Putative Sp1 Binding Sites
Open Access
Abstract
The vitamin D receptor (VDR) mediates 1,25-dihydroxyvitamin D3 pleiotropic biological actions through transcription regulation of target genes. The expression levels of this ligand-activated nuclear receptor are regulated by multiple mechanisms both at transcriptional and post-transcriptional levels. Vitamin D3 is the natural VDR activator, but other molecules and signaling pathways have also been reported to regulate VDR expression and activity. In this study, we identify valproic acid (VPA) and natural short-chain fatty acids (SCFAs) as novel transcriptional activators of the human VDR (hVDR) gene. We further report a comprehensive characterization of VPA/SCFA-responsive elements in the 5′ regulatory region of the hVDR gene. Two alternative promoter DNA regions (of 2.4 and 3.8 kb), as well as subsequent deletion fragments, were cloned in pGL4-LUC reporter vector. Transfection of these constructs in HepG2 and human Upcyte hepatocytes followed by reporter assays demonstrated that a region of 107 bp (from −107 to −1) upstream of the transcription start site in exon 1a is responsible for most of the increase in transcriptional activity in response to VPA/SCFAs. This short DNA region is GC-rich, does not contain an apparent TATA box, and includes two bona fide binding sites for the transcription factor Sp1. Our results substantiate the hypothesis that VPA and SCFAs facilitate the activity of Sp1 on novel Sp1 responsive elements in the hVDR gene, thus promoting VDR upregulation and signaling. Elevated hepatic VDR levels have been associated with liver steatosis and, therefore, our results may have clinical relevance in epileptic pediatric patients on VPA therapy. Our results could also be suggestive of VDR upregulation by SCFAs produced by gut microbiota.Keywords
Funding Information
- Instituto de Salud Carlos III-FIS (PI20/00690, IJC2018-036209-I)
- MCIN/AEI/10.13039/501100011033 (PI20/00690, IJC2018-036209-I)
This publication has 72 references indexed in Scilit:
- Valproic acid augments vitamin D receptor-mediated induction of CYP24 by vitamin D3: A possible cause of valproic acid-induced osteomalacia?Toxicology Letters, 2011
- MMP28 gene expression is regulated by Sp1 transcription factor acetylationBiochemical Journal, 2010
- Sp1 Phosphorylation and Its Regulation of Gene TranscriptionMolecular and Cellular Biology, 2009
- Sp1: Emerging roles—Beyond constitutive activation of TATA-less housekeeping genesBiochemical and Biophysical Research Communications, 2008
- Trichostatin A Induces Transforming Growth Factor β Type II Receptor Promoter Activity and Acetylation of Sp1 by Recruitment of PCAF/p300 to a Sp1·NF-Y ComplexJournal of Biological Chemistry, 2005
- Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular DifferentiationCancer Research, 2004
- Anti‐tumor mechanisms of valproate: A novel role for an old drugMedicinal Research Reviews, 2002
- Antitumor activity of sodium valproate in cultures of human neuroblastoma cellsAnti-Cancer Drugs, 1996
- 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Retinoic acid modulation of 1,25(OH)2 vitamin D3 receptors and bioresponse in bone cells: Species differences between rat and mouseBiochemical and Biophysical Research Communications, 1985